The Latest Advances in Peptide Receptor Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors

J Nucl Med. 2023 Jan 5;jnumed.122.264422. doi: 10.2967/jnumed.122.264422. Online ahead of print.

Authors

Elif Hindié¹, Eric Baudin², Rodney Hicks³, David Taïeb⁴

Affiliations

¹ Dept of Nuclear Medicine, CHU Bordeaux, University of Bordeaux, Institut Universitaire de France, France.
² Department of Endocrine Oncology and Imaging, Gustave Roussy Cancer Campus Grand Paris, France.
³ Department of Medicine, St Vincent's Hospital Medical School, the University of Melbourne, Australia.
⁴ Nuclear Medicine, La Timone Hospital, CERIMED, Aix-Marseille University, France.

PMID: 36604184
DOI: 10.2967/jnumed.122.264422

No abstract available

Keywords: Neuroendocrine; Radionuclide Therapy; neuroendocrine tumors; precision medicine; somatostatin receptor; targeted radionuclide therapy.